Regulation of Cancer-Associated miRNAs Expression under Hypoxic Conditions

Table 3

Effect of hypoxia on miRNAs expression and drug resistance.

miRNA	Cancer type		Drug	References
miR-24	Breast	↑	Cisplatin	[130]
miR-27a	Ovarian	↑	Paclitaxel	[38]
miR-98	Head/neck	↑	Doxorubicin, cisplatin	[42]
miR-191	Breast	↑	Doxorubicin	[55]
miR-196b	Liver	↓	Etoposide	[28]
miR-199a	Osteosarcoma	↓	Cisplatin	[90]
miR-199a-3p	Liver	↓	Doxorubicin	[131]
miR-210	Colon	↑	5-fluorouracil	[132]
miR-210-3p	Glioblastoma	↑	Temozolomide	[133]
miR-224-3p	Glioblastoma	↓	Temozolomide	[96]
miR-338-3p	Liver	↑	Sorafenib	[98]
miR-338-5p	Colon	↓	Oxaliplatin, 5-fluorouracil, doxorubicin	[99]
miR-421	Breast	↑	Cisplatin	[69]
miR-424	Melanoma, colon, glioblastoma	↑	Doxorubicin, etoposide	[134]
miR-494	Breast	↓	Docetaxel	[103]
miR-497	Glioblastoma	↑	Temozolomide	[72]
miR-675-5p	Colon	↑	5-Fluorouracil	[74]
miR-758-3p	Esophageal	↓	Cisplatin	[108]

Up or down arrows indicate increasing and decreasing miRNAs expression, respectively.